Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

980 trials

NCT06885164
Recruiting
Remote Monitoring of Cardiac Mechanics in Heart Failure Patients
Not applicable · Denmark · 2 sites
Registry update: 16 Jan 2026
NCT07023536
Recruiting
Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure
Not applicable · Italy · 1 site
Registry update: 11 Mar 2026
NCT06670001
Recruiting
MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction
Not applicable · United States · 1 site
Registry update: 6 Oct 2026
NCT06601465
Recruiting
COgnitioN With VERiciGuat Evaluation in Heart Failure
Phase 2 · Canada · 4 sites
Registry update: 25 Aug 2026
NCT05204693
Recruiting
Visa-versa! Breaking Instead of Pushing the Pedals-C
Not applicable · Switzerland · 1 site
Registry update: 13 Jun 2025
NCT07047547
Recruiting
A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure
Not applicable · China · 1 site
Registry update: 9 Jul 2025
NCT06956560
Recruiting
Platelet Derived Growth Factor Receptor ß (PDGFRß) Imaging in Cardiac Fibrosis
Not applicable · Sweden · 1 site
Registry update: 8 Aug 2025
NCT07016815
Recruiting
Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study
Not applicable · Hong Kong · 1 site
Registry update: 30 Jul 2025
NCT06935370
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Phase 3 · Argentina, Belgium, Bulgaria, Brazil, Canada, Chile, China, Colombia, Czechia, Germany, Denmark, Spain, United Kingdom, Hungary, India, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Romania, Serbia, Saudi Arabia, Slovakia, Taiwan, United States, Vietnam · 592 sites
Registry update: 28 Oct 2026
NCT06762964
Recruiting
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
Phase 2 · United States · 1 site
Registry update: 6 May 2026
NCT06907017
Recruiting
CorWave LVAS FIH Study
Not applicable · Australia, Kazakhstan · 3 sites
Registry update: 3 Aug 2026
NCT07094737
Recruiting
The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P) Registry: An Observational Study on Cardiac Rehabilitation in Patients With Coronary Disease or Heart Failure
Not applicable · Italy · 1 site
Registry update: 29 Sept 2026
NCT06929169
Recruiting
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Phase 2 · Argentina · 1 site
Registry update: 16 Apr 2025
NCT06929806
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Phase 3 · Bulgaria, Czechia, Denmark, Croatia, Hungary, Lithuania, Latvia, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, United States · 146 sites
Registry update: 5 Oct 2026
NCT06587854
Recruiting
a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure
Not applicable · Netherlands · 1 site
Registry update: 10 Sept 2025
NCT07029906
Recruiting
pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure
Not applicable · United Kingdom · 1 site
Registry update: 19 Jun 2025
NCT05934565
Recruiting
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
Not applicable · United States · 2 sites
Registry update: 29 Sept 2026
NCT06726109
Recruiting
The FOCUS-ADHF Registry
Not applicable · Belgium, Italy · 4 sites
Registry update: 6 May 2025
NCT06831825
Recruiting
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
Phase 1 · United States · 1 site
Registry update: 27 Apr 2025
NCT04696523
Recruiting
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
Phase 2 · Finland, Sweden · 7 sites
Registry update: 1 May 2025

Ordered by registry start date. Freshness and sponsorship never change the order.